Mechanical circulatory support
Innovative mechanical heart and lung support
Mechanical circulatory support devices can temporarily or permanently maintain proper blood flow by supporting or replacing the heart’s pumping function. They can also add oxygen and remove carbon dioxide from the blood while the heart and lungs rest. These devices deliver critical, life-sustaining support for people with advanced heart failure, respiratory failure, and other severe conditions involving the heart or lungs. MCS can also be used for patients awaiting a heart transplant or lung transplant.
Key benefits of MCS include:
- Support for better heart and lung function
- Improved survival rates for people who are critically ill
- Enhanced quality of life
- Aid in heart and lung function recovery in certain people
Penn Medicine’s mechanical circulatory support program offers the most innovative heart and lung support options available today. We’re the only center in the region and one of the few nationwide that uses a minimally invasive approach (lateral thoracotomy) to implant devices in certain patients, improving recovery and delivering excellent surgical outcomes. We also specialize in treating high-risk patients, including those turned away by other hospitals and referred to us for advanced heart or lung failure therapies.
Penn Heart and Lung Rescue
Our rapid referral program can treat anyone, at any hospital, for cardiovascular emergencies and severe but reversible respiratory failure. We help stabilize the person and transport them to our center to receive our advanced therapies and treatments.
How we use MCS devices
Each MCS device is designed to address specific patient conditions. Our team has years of experience in selecting the right devices and therapies based on each patient’s unique needs. At Penn Medicine, we use mechanical circulatory support in several ways.
Many people live with advanced heart failure, and the shortage of donor hearts can delay transplants. MCS helps support the heart until a donor heart becomes available. We have also pioneered the use of extracorporeal membrane oxygenation (ECMO) and offer Lung Rescue (VV ECMO) to support patients with severe respiratory failure.
MCS allows our specialists time to stabilize and assess critically ill patients. During this time, we evaluate their risk factors to determine if they are candidates for a heart or lung transplant once they are stable enough for surgery.
Penn Medicine is one of the highest volume centers in the region to use ventricular assist devices (VADs) to support recovery from cardiogenic shock or reversible heart failure. We implant a device that allows the heart to rest for weeks, months, or even years. Once the heart is strong enough, the device is removed.
For patients who aren’t eligible for a transplant, a VAD can provide lifelong support, improving both survival and quality of life.
Mechanical circulatory support treatment
Choosing the right MCS treatment option for your condition requires a thorough evaluation of your health, medical history, physical exams, lab tests, heart function, and care goals. At Penn Medicine, a multidisciplinary team will assess whether MCS is right for you. This collaborative care is delivered by our expert staff, including cardiovascular surgeons, cardiothoracic surgeons, heart failure specialized cardiologists, cardiac anesthesiologists, respiratory therapists, social workers, cardiac nurses, nutrition specialists, psychiatrists, and technicians.
We offer these MCS devices and therapies.
Recognized excellence in life support
When you choose Penn Medicine for mechanical circulatory support, you’ll benefit from a team with years of experience. As a nationally top-ranked hospital for cardiac care, our heart surgeons perform over 3,000 procedures each year. We provide more treatment options for heart and lung care than any other program in our region. We work with every major MCS device and offer minimally invasive options.
The Hospitals of the University of Pennsylvania—Penn Presbyterian Medical Center has received the Excellence in Life Support Award by the Extracorporeal Life Support Organization (ELSO) and is recognized as a Gold Level Center of Excellence. The Penn Lung Rescue program meets or exceeds ELSO’s standards. We’re also recognized for our exceptional commitment to evidence-based practices and quality measures, patient satisfaction, continuing education, staff training, and ongoing clinical care.
Penn Medicine Lancaster General Hospital has received the Silver Level Path to Excellence award from ELSO.
We’re also known for:
- Treating high-risk patients: With our unmatched expertise, many high-risk patients are referred to us for advanced heart failure and respiratory failure therapies when other hospitals are unable to offer treatment.
- Leading the region in ECMO: Extracorporeal membrane oxygenation (ECMO) is a lifesaving therapy for people with complex heart or lung conditions. We are one of the highest-volume centers using ECMO support and offer mobile ECMO to rescue patients too sick to travel.
- Device optimization: We’re the only center in the region that routinely optimizes devices using hemodynamic and echocardiographic data at three and 12 months after surgery. This approach helps your ventricular assist device function at its best. Our proactive method maximizes device support and improves patient symptoms.
- Clinical innovation: We’ve been involved in clinical trials for every major mechanical circulatory support device and continue to lead groundbreaking studies. Our surgeons and cardiologists are national leaders, shaping the design and advancement of MCS therapy in both medical societies and technological development.
Our doctors
Our providers work with you to plan and deliver exceptional treatment and personalized care.
Locations
Our hospitals, multispecialty medical centers, pharmacies, labs and more offer outstanding, personalized care for patients all across the region.
Related articles
$25M trial uses phones to gamify steps, fight heart disease
Penn Medicine researchers have been awarded $25M to conduct a trial using smartphones to fight heart disease.
Study identifies new prognostic biomarker for heart failure
Bloodstream levels of a protein fragment called endotrophin can be used to predict outcomes in patients with a common form of heart failure.
Patient stories
ECMO saves recovering cancer survivor from lung failure
From cancer survivor to lung failure, Joey Porch’s journey took a miraculous turn with the help of the Penn Lung Rescue team
Home ventilation for respiratory failure: Jacquie’s story
Jacquie Eubanks never suspected respiratory failure could be causing her shortness of breath. Home breathing treatment helps her live a fulfilling life.